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Background: Menstrual migraine without aura (MM) affects approximately 20% of female migraineurs in the
general population. The aim of the present study was to investigate the influence of contraception on the attacks
of migraine without aura (MO) in women with MM.
Findings: 141 women from the general population with a history of MM according to the International
Classification of Headache Disorders II (ICHD II) were interviewed by a headache specialist. Of 49 women with a
history of MM currently using hormonal contraception, 23 reported amenorrhoea. Significantly more women with
amenorrhoea reported no MO- days during the preceding month compared to women without amenorrhoea
(OR 16.1; 95% confidence interval (CI) 1.8-140.4; P = 0.003). A reduction of MO-frequency was more often reported in
women with than without amenorrhoea (OR 3.5; 95% CI 1.1-11.4; P = 0.04).
Conclusion: Amenorrhoea leads to a reduction of MO-frequency in women with MM using hormonal contraceptives.
Future prospective studies on MM should focus on contraceptive methods that achieve amenorrhoea.
Keywords: Menstrual migraine without aura; Migraine; Amenorrhoea; Contraception; Hormones; Estrogen; Progestin;
Prostaglandins; OvulationFindings
Introduction
Menstrual migraine without aura (MM) affects approxi-
mately 20% of female migraineurs in the general popula-
tion [1,2]. The appendix criteria of the International
Classification of Headache Disorders (ICHD) II and III
beta version defines MM as attacks of migraine without
aura (MO) which occur on day 1 ± 2 (i.e. days −2 to +3)
of menstruation in at least 2/3 menstrual cycles [3,4].
The pathophysiology of MM is not fully understood and
probably heterogeneous. Clinical observations indicate an
increased incidence of MO in conditions with falling levels
of plasma estrogen such as in the perimenstrual phase
of the menstrual cycle [5], the hormone-free interval in
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in any medium, provided the original work is p[6], and in the days directly following a childbirth [7]. Ex-
perimental studies have shown that MM can be prevented
by supplementing estrogen at the time of the natural de-
cline during the late luteal phase of the cycle [8]. This led
to the hypothesis that MM is triggered by the decline in
plasma estrogen during the late luteal phase of the cycle
following a period of oestrogen ‘priming’ [9]. Perimenstrual
prostaglandin may also play a direct or indirect role in trig-
gering MM attacks [10].
Anecdotally, MM is more likely to improve in women
who achieve amenorrhoea [11], but data regarding this pos-
sible effect are lacking.
The aim of our study was to explore the influence of
amenorrhoea on all MO attacks in women with MM using
hormonal contraceptive methods.
Material and method
A random sample of 5000 women from the general popula-
tion aged 30–34 years received a mailed screening
questionnaire about their migraine and the relationship
of attacks to menstruation. Women with self-reportedn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ache days/year were invited to participate in a semi-
structured headache interview six years later. At that time
the participants were aged 36–40 years. The interview in-
cluded questions about migraine, menstruation and contra-
ception. All women were asked about type of current
hormonal contraception, duration of use and whether
amenorrhoea had arisen after initiating the method.
Additionally, a subgroup analysis of contraceptive methods
which are expected to inhibit ovulation (i.e. CHC,
desogestrel-only pill and depot medroxyprogesterone acet-
ate injection) and methods which are expected not to in-
hibit ovulation (i.e. LNG-IUS and progestin-only mini-pill)
was made. Headaches were classified according to the
ICHD II-criteria, including the appendix criteria for men-
strual migraine (i.e. A 1.1.1 pure menstrual migraine and A
1.1.2 menstrually-related migraine) [4]. In the current
paper, the term menstrual migraine (MM) covers both
A1.1.1 and A 1.1.2. Amenorrhoea was defined as the ab-
sence of menses for three months in a woman with previ-
ously normal menstruation [12].
The following question was evaluated: “Did your MO
change after onset of current contraceptive method?”
with respect to frequency, intensity and duration. This
question referred to all MO-attacks, not exclusively
MM-attacks, and responses were categorized as; fewer/
less severe/shorter, no change, more frequent/more se-
vere/longer duration. In addition, women were asked to
state the number of migraine days per month on average
over the last three months preceding the interview.
The interviews were conducted by a neurologist with
special interest in headache disorders (KGV). A more
exhaustive description of the method has been published
elsewhere [2].Statistics
The data were analyzed using Statistical Package of So-
cial Sciences (SPSS) version 20. A 2-sided Fisher’s exact
test mid-p variant was used to compare two groups with
categorical variables. Differences regarding self-reported
changes of MO-frequency are presented as odds ratio
(OR) with 95% confidence intervals. Due to skewed
distribution and low number of participants, non-
parametric tests (Independent samples median test) were
used to calculate differences in continuous variables. A
p-level <0.05 was considered significant.Ethics
The study was approved by the Norwegian Regional
Committee for Medical Research Ethics and the Norwe-
gian Data Protection Authorities. The participants re-
ceived written and verbal information about the project
and inclusion was based on informed consent.Results
The questionnaire response rate was 73%. Of 360 women
meeting the inclusion criteria, four had emigrated, nine had
insufficient language skills, 39 did not reply to five or more
phone calls and 71 declined to participate due to lack of
time, no interest or acute illness. Of the remaining 237
women interviewed, 141 women were diagnosed with MM.
Forty-nine women were current users of hormonal contra-
ception, of whom 23 reported amenorrhoea (Figure 1).
Women with amenorrhoea had used current contraceptive
method for 10–132 months and significantly longer than
women without amenorrhoea (Table 1). Migraine prophy-
laxis was used by four women, of whom one had amenor-
rhoea (Table 1).
Significantly more women with amenorrhoea reported
a reduction of MO-frequency after initiation of current
contraceptive method than women with menstrual/
withdrawal bleeds (OR 3.5, 1.1-11.4, P = 0.04). Intensity
and duration was not significantly different in the two
subgroups (Table 2). Only 1/23 woman with amenorrhoea
reported increased frequency, intensity and duration of
MO-attacks, while 3/26 women without amenorrhoea
reported increased frequency and 2/26 longer duration
and higher pain intensity. The remaining reported no
change.
A larger proportion of amenorrhoeic women reported
no MO-days during the preceding month than those
with menstrual/withdrawal bleeds (OR 16.1, 1.8-140.4,
P = 0.003).
A subgroup analysis of methods with and without
expected inhibition of ovulation showed that reduced
frequency of MO was less often reported in women using
expected anovulatory contraceptive methods than in women
using methods with expected preserved ovulation (OR 0.2,
0.1-0.9, P = 0.03). Intensity and duration of MO-attacks were
not different between the two subgroups.
Discussion
In this study, achievement of amenorrhoea was associated
with a higher proportion of self-reported reduction of MO-
frequency in women with MM compared to women who
were not amenorrhoeic.
Based on the hypothesis that estrogen withdrawal trig-
gers MM attacks, the focus in previous studies on MM
has been to avoid this estrogen drop and little attention
has been directed toward other potential mechanisms
[13,8,14].
CHCs contain a combination of estrogens and a proges-
tin most of which have a standard formulation of 21 days
active hormones followed by a 7-day hormone-free interval.
The contraceptive effect of CHCs is primarily from sup-
pression of ovulation. During the hormone-free interval,
usually associated with withdrawal bleedings, migraine is
more likely to occur. This has been explained by the decline
Figure 1 Flow chart of the study. LNG-IUS = Levonorgestrel interuterine system. CHC = combined hormonal contraception.
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CHC, such as formulations with 84 days active hormones
before a 7-day hormone-free interval, are associated with
reduced incidence of MM attacks, an effect which has been
explained by stabilization of estrogens throughout the cycle
[14]. Notably, these regimens are also associated with re-
duced incidence of withdrawal bleeds. It is unknown
whether it is the stabilization of estrogens or achievement
of amenorrhoea – or both, that are the actual mechanisms
of action. A shortened hormone-free interval, from a 21/7-
to a 24/4-regimen, in women taking CHC showed a posi-
tive effect on MM with significant reduction of attack
duration and pain intensity. This effect was explained by a
shorter period of hypoestrogenism in the 24/4-regimenTable 1 Population variables
Amenorrhoea (n =
Continuous variables1
Age at migraine onset 18
Age at menstrual migraine onset 25
Duration of hormonal contraceptive use (months) 48
Dichotomous variables2
Migraine prophylaxis, n (%) 1 (4)
Triptan use, n (%) 15 (65)
Ever consulted a neurologist for migraine, n (%) 8 (35)
Endometriosis 2 (9)
1Independent samples median test. 2Fischers exact mid-p test.[15]. Differences in bleeding profiles between the groups
were not reported.
Progestin-only methods provide contraceptive effects in
different fields, depending on the doses and route of admin-
istration. Ovulation is usually inhibited by high doses, while
lower doses act by thickening of cervical mucus and endo-
metrial suppression [16]. Estrogen-withdrawal is also pre-
vented with some progestin-only methods, provided that
ovarian activity is sufficiently suppressed. The effect of con-
tinuous oral progestin, given in doses high enough to in-
hibit ovulation, was evaluated in a small sample of female
migraineurs of whom 13/22 reported MM [11]. Only 5/13
women with MM had a ≥50% reduction in migraine fre-










Table 2 Effects of amenorrhoea on migraine without aura (MO) in women with menstrual migraine (MM)
Amenorrhoea (N = 23) Menstruation/withdrawal bleeding (N = 26)
Proportions with reduced % (n) % (n) OR 95% CI p
Attack frequency 61 (14) 31 (8) 3.5 1.1-11.4 0.04
Attack intensity 30 (7) 19 (5) 1.8 0.5-6.9 0.39
Attack duration 30 (7) 23 (6) 1.5 0.4-5.2 0.58
Proportion of women reporting no MO-days during the preceding month 39 (9) 4 (1) 16.1 1.8-140.4 0.003
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bleeding. The occurrence of breakthrough bleeding was
considered to result from incomplete suppression of ovar-
ian activity resulting in fluctuating estrogen levels, which
can occur even when ovulation is inhibited. This failure to
achieve amenorrhoea, may explain the “disappointing” re-
sults. The two patients who achieved amenorrhoea, likely
to be associated with greater ovarian suppression, became
headache free [11].
On this basis, it could be hypothesized that MM will per-
sist in women using contraceptive methods that result in
estrogen withdrawal as a consequence of the endogenous
ovarian cycle (e.g. LNG-IUS) or withdrawal of exogenous
estrogen (CHC). Further, progestin-only methods that in-
hibit ovulation (e.g. desogestrel pill), should be associated
with improvement in MM.
However, we found that the benefit of amenorrhoea was
independent of the effect of the method on ovulation. Of
the amenorrhoeic group, 19/23 were using the LNG-IUS.
The plasma levels of progesterone and estrogens are similar
in women with and without amenorrhoea using the LNG-
IUS. The incidence of ovulation is also similar in both
groups [17]. This indicates that absence of menstrual bleed-
ing is not a predictor of ovarian function but a result of the
local effect within the endometrial cavity with strong sup-
pression of growth and induction of endometrial insensitiv-
ity to ovarian estradiol; only about 15% of women using
LNG-IUS develop anovulation [17].
Of the group who were not amenorrhoeic, 24/26
were using methods associated with continuing estrogen
withdrawal (LNG-IUS = 12, CHC= 11, progestin-only
‘mini-pill’ = 1). Hence the benefit of amenorrhoea appears
to be independent of the effect of the method on estrogen-
withdrawal. A possible explanation may be the oligo-
amenorrhoea that follows 6–12 months after insertion of
LNG-IUS and consequent effect on prostaglandins, which
have been implicated in MM, particularly associated with
dysmenorrhoea [18]; a reduction in menstrual flow is asso-
ciated with reduced levels of prostaglandins reaching the
systemic circulation in the early menstrual phase, poten-
tially reducing the effect on migraine.
Strengths and limitations
This is one of few studies exploring the effect of progestin-
induced amenorrhoea in menstrual migraineurs. Thewomen were diagnosed by a neurologist after a clinical
interview according to the ICHD II-criteria, but the diagno-
sis was not confirmed by prospective headache diaries. The
retrospective design is subject to recall bias, but since many
women reported amenorrhoea at time of interview, it was
not possible to confirm the MM-diagnosis by prospective
diaries. The MM-diagnoses are consequently based on
symptoms experienced before achievement of amenorrhoea.
Women with amenorrhoea had used the contraceptive
method significantly longer than women without amen-
orrhoea. This may be explained by satisfaction with the
method, but other reasons such as wish to avoid preg-
nancy or co-morbid menstrual disorders could also
explain this difference. Our results may have been influ-
enced by changes in medication. However, migraine
prophylaxis was used by more women with menstru-
ation/withdrawal bleeds than amenorrhoeic women.
We made a subgroup analysis of methods with/with-
out inhibition of ovulation. The effect of each contracep-
tive method was based on the known mechanism of
action in the majority of women, but it is acknowledged
that ovulation can occur in some women using oral des-
ogestrel and ovulation is inhibited in some women using
the LNG-IUS, irrespective of amenorrhoea.
Due to the relatively small number of women with
MM using hormonal contraception and the retrospective
design of our study, the results should be interpreted
with some caution and need confirmation by a larger
prospective study.
Conclusion and the future
Women with MM benefited from using contraceptive
methods leading to amenorrhoea, while methods with
expected anovulation had no such effect. These findings
suggest that neither inhibition of ovulation nor prevention
of estrogen withdrawal are necessary for the management
of MM, and that more focus should be given to amenor-
rhoea. Future studies should also explore the underlying
pathophysiology.
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